Purpose: To provide an in-depth analysis of the association of peripheral lymphocytes and the disease activity of thyroid eye disease (TED).

Methods: This retrospective study enrolled 65 active TED patients and 46 inactive TED patients. Comparative analyses of peripheral lymphocyte subsets were conducted between active and inactive patients. Subgroup analyses were performed based on sex, age, disease duration, and severity. Correlation analyses explored the associations between lymphocyte subsets and TED activity indicators. Prediction models for TED activity were established using objective indicators.

Results: Significantly elevated levels of CD3CD4 T cells were observed in active TED patients compared to inactive patients (P = 0.010). Subgroup analyses further revealed that this disparity was most prominent in females (P = 0.036), patients aged 50 years and younger (P = 0.003), those with long-term disease duration (P = 0.022), and individuals with moderate-to-severe disease (P = 0.021), with age exerting the most substantial impact. Subsequent correlation analysis confirmed the positive association between CD3CD4 T cells and the magnetic resonance imaging indicator of TED activity among patients aged 50 years and younger (P = 0.038). The combined prediction models for TED activity, established using objective indicators including CD3CD4 T cells, yielded areas under curve of 0.786 for all patients and 0.816 for patients aged 50 years and younger.

Conclusions: Peripheral CD3CD4 T cells are associated with disease activity of TED, especially in patients aged 50 years and younger. Our study has deepened the understanding of the peripheral T cell profiles in TED patients.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00417-024-06496-9DOI Listing

Publication Analysis

Top Keywords

cd3cd4 cells
20
ted patients
20
ted activity
16
patients aged
16
aged 50 years
16
disease activity
12
50 years younger
12
patients
11
ted
9
peripheral cd3cd4
8

Similar Publications

Mepolizumab in patients with lymphoid variant hypereosinophilic syndrome: a multi-center prospective study.

J Allergy Clin Immunol

January 2025

Department of Internal Medicine, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium; Institute for Medical Immunology, Université Libre de Bruxelles, Brussels, Belgium.

Background: Hypereosinophilic syndrome (HES) is characterized by blood and tissue hypereosinophilia causing organ damage and/or dysfunction. Mepolizumab, an anti-IL-5 antibody, has recently been approved in this indication. In lymphoid variant (L-)HES, eosinophil expansion is driven by IL-5-producing clonal CD3CD4 T cells.

View Article and Find Full Text PDF

Due to the genetic diversity between the mother and the fetus, heightened control over the immune system during pregnancy is crucial. Immunological parameters determined by clinicians in women with idiopathic recurrent spontaneous abortion (RSA) include the quantity and activity of Natural Killer (NK) and Natural Killer T (NKT) cells, the quantity of regulatory T lymphocytes, and the ratio of pro-inflammatory cytokines, which indicate imbalances in Th1 and Th2 cell response. The processes are controlled by immune checkpoint proteins (ICPs) expressed on the surface of immune cells.

View Article and Find Full Text PDF

Background: Patients with DNA mismatch repair-proficient/microsatellite stable (pMMR/MSS) colorectal cancer (CRC), which accounts for 85% of all CRC cases, display a poor respond to immune checkpoint inhibitors (i.e., anti-PD-1 antibodies).

View Article and Find Full Text PDF

Targeting CCR4 with mogamulizumab in refractory CD3CD4 lymphocytic-variant hypereosinophilic syndrome.

Haematologica

June 2024

Service de médecine interne et d'immunologie clinique, Centre de Référence des Syndromes Hyperéosinophiliques (CEREO), CHU Lille, Lille, France; INFINITE - Institute for Translational Research in Inflammation, Université de Lille, Lille, France; Laboratoire d'immunologie, CHU Lille, Lille.

View Article and Find Full Text PDF

Production and characterization of anti-porcine CXCL10 monoclonal antibodies.

Cytokine

February 2024

Animal Parasitic Diseases Laboratory, BARC, ARS, USDA, Beltsville, MD, USA. Electronic address:

Research on C-X-C motif chemokine ligand 10 (CXCL10) has been widely reported for humans and select animal species, yet immune reagents are limited for pig chemokines. Our goal is to provide veterinary immunologists and the biomedical community with new commercial immune reagents and standardized assays. Recombinant porcine CXCL10 (rPoCXCL10) protein was produced by yeast expression and used to generate a panel of α CXCL10 monoclonal antibodies (mAbs).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!